Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy
Research To Practice | Oncology Videos · Dr. Neil Love
May 16, 202537m 9s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:
- Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00)
- Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50)
- Published Clinical Data Involving Axi-cel (10:24)
- Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34)
- Published Clinical Data Involving Tis-cel (19:47)
- Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43)
- Published Clinical Data Involving Liso-cel (26:05)
- Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48)
- Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35)
- Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59)